소외열대질환(NTD) 진단 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 질환별, 진단 방법별, 서비스 유형별, 최종 용도별, 지역별 부문, 경쟁(2020-2030년)

Neglected Tropical Diseases Diagnosis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease, By Diagnostic Method, By Service Type, By End Use, By Region & Competition, 2020-2030F

US $ 4,500 ￦ 6,385,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,805,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,352,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

세계 소외열대질환 진단 시장은 2024년 62억 달러로 평가되었고, 2030년까지 4.09%의 연평균 복합 성장률(CAGR)을 나타내며 예측 기간 동안 괄목할 만한 성장을 이룰 것으로 예상됩니다.

소외열대질환(Neglected Tropical Diseases, NTDs)은 주로 전 세계 저소득층과 열대 및 아열대 지역 사람들이 앓고 있는 감염성 질환군을 말합니다. NTDs는 적절한 의료 서비스, 깨끗한 물, 위생 시설 및 예방책에 대한 접근성이 부족한 소외되고 빈곤한 지역사회에서 확산되는 것이 특징이며, NTDs는 세계에서 가장 가난하고 소외된 사람들, 특히 농촌과 도시 빈민가에 사는 사람들에게 불균형적으로 영향을 미칩니다. 불균형적으로 영향을 미칩니다. NTDs는 박테리아, 바이러스, 기생충, 원충 등 다양한 감염 요인에 의해 발생하며, 이러한 지역 사회는 기본적인 의료 서비스를 받지 못하는 경우가 많습니다. 이러한 질병의 전파는 종종 환경적 요인이나 모기나 파리와 같은 매개충과 관련이 있으며, NTD 옹호 단체와 인식 개선 캠페인은 이러한 질병에 대한 일반 대중과 정치적 인식을 높이는 데 중요한 역할을 해왔습니다. 그 결과, 진단 및 치료 노력에 대한 지원이 증가하고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	62억 달러
시장 규모 : 2030년	78억 2,000만 달러
CAGR : 2025-2030년	4.09%
급성장 부문	병원 및 클리닉
최대 시장	북미

시장 성장 촉진요인

진단의 발전

주요 시장 이슈

고감도 및 특이적 검사 부족

주요 시장 동향

조기 발견의 중요성

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 소외열대질환(NTD) 진단 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 질환별(뎅기열, 치쿤구니야, 광견병, 부룰리 궤양, Yaws, 림프사상충증, 기생충/낭포충증, 드라쿤쿨라증, 기타)
  • 진단 방법별(기존, 분자/현대형)
  • 서비스 유형별(집중 서비스, POC 서비스)
  • 최종 용도별( 임상 실험실, 병원/진료소, 재택 헬스케어)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 아시아태평양의 소외열대질환(NTD) 진단 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 인도
  • 호주
  • 일본
  • 한국

제7장 유럽의 소외열대질환(NTD) 진단 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 스페인
  • 이탈리아
  • 영국

제8장 북미의 소외열대질환(NTD) 진단 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 멕시코
  • 캐나다

제9장 남미의 소외열대질환(NTD) 진단 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 소외열대질환(NTD) 진단 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병(M&A)

제13장 세계의 소외열대질환(NTD) 진단 시장 : SWOT 분석

제14장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제15장 PESTEL 분석

제16장 경쟁 구도

• F. Hoffmann-La Roche Ltd
• Abbott Laboratories Inc.
• Thermo Fisher Scientific Inc.
• ZeptoMetrix LLC
• InBios International, Inc.
• Genome Diagnostics Pvt. Ltd.
• Omega Diagnostics Group Plc
• Coris Bioconcept
• Oscar medicare Pvt Ltd.
• DiaSys Diagnostics Systems GmbH

제17장 전략적 제안

제18장 리서치사에 대해 & 면책사항

LSH

영문 목차

영문목차

Global Neglected Tropical Diseases Diagnosis Market was valued at USD 6.20 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 4.09% through 2030. Neglected Tropical Diseases (NTDs) refer to a group of infectious diseases that primarily affect populations in low-income and tropical or subtropical regions of the world. These diseases are characterized by their prevalence in marginalized and impoverished communities, often lacking access to adequate healthcare, clean water, sanitation, and preventive measures. NTDs disproportionately affect the world's poorest and most marginalized populations, particularly those living in rural or urban slum areas. These communities often lack access to basic healthcare services. NTDs are caused by a variety of infectious agents, including bacteria, viruses, parasites, and protozoa. The transmission of these diseases is often linked to environmental factors and vectors, such as mosquitoes or flies. NTD advocacy groups and awareness campaigns have played a significant role in increasing public and political awareness about these diseases. This has resulted in greater support for diagnosis and treatment efforts.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 6.20 Billion
Market Size 2030	USD 7.82 Billion
CAGR 2025-2030	4.09%
Fastest Growing Segment	Hospitals & Clinics
Largest Market	North America

Key Market Drivers

Advancements in Diagnostics

Molecular techniques such as Polymerase Chain Reaction (PCR) and Nucleic Acid Amplification Tests (NAATs) have revolutionized NTDs diagnosis. They allow for the detection of the genetic material of pathogens with high sensitivity and specificity. Molecular diagnostics are particularly useful for diseases like Chagas disease and Leishmaniasis. For instance, according to a 2024 NCBI article, advancements in artificial intelligence are enhancing medical computer-aided diagnosis, improving accuracy, efficiency, and early disease detection for better patient outcomes.

Also, in May 2022, medical technology company Anitoa Systems launched a portable RT-PCR test for dengue virus detection, expanding its Maverick RT-PCR device line. This multiplex test detects multiple target genes linked to severe dengue, ensuring early and accurate diagnosis. Point-of-Care Testing (POCT) devices have been developed for various NTDs, enabling rapid and on-site diagnosis. These portable devices are especially valuable in remote and resource-limited settings where access to centralized laboratories is limited. Examples include rapid diagnostic tests for malaria and dengue. Serological tests detect specific antibodies produced by the immune system in response to infection. Advances in serological assays have improved their accuracy and made them more widely available for diagnosing diseases like schistosomiasis and lymphatic filariasis. Some NTDs can be diagnosed by detecting specific antigens produced by the pathogens. Antigen detection tests are valuable for diseases like African sleeping sickness and urinary schistosomiasis.

Key Market Challenges

Lack of Sensitive and Specific Tests

Many NTDs share symptoms with other diseases or have multiple stages, making accurate diagnosis difficult. When sensitive and specific tests are lacking, there's a higher risk of misdiagnosis or underdiagnosis, leading to delayed or inadequate treatment. Accurate diagnosis is essential for determining the appropriate treatment regimen. Without sensitive and specific tests, healthcare providers may resort to empirical treatment, which can result in unnecessary healthcare costs and potential drug resistance. NTDs control and elimination programs rely on accurate data to target affected populations effectively. Inaccurate diagnosis can lead to misallocation of resources, potentially slowing down progress in controlling these diseases. For tracking the prevalence and distribution of NTDs, sensitive and specific tests are crucial. Inaccurate diagnostic tools can lead to inaccurate disease surveillance data, hindering the ability to detect outbreaks or changes in disease patterns. Diagnostic tools are fundamental in research efforts related to NTDs, including drug and vaccine development. Insensitive or nonspecific tests can slow down the research process and hinder the identification of potential therapeutic targets. Patients may undergo multiple tests, sometimes invasive, to confirm an NTD diagnosis due to the lack of definitive tests. This can result in a physical and psychological burden on affected individuals. Limited healthcare resources in endemic regions should be used efficiently. Sensitive and specific tests are essential for targeting interventions to those who need them most, thereby optimizing resource allocation.

Key Market Trends

Focus on Early Detection

Early detection allows for prompt initiation of treatment, which can lead to better outcomes for patients. For many NTDs, early treatment can prevent disease progression and complications. Early diagnosis and treatment can help break the cycle of transmission of NTDs. By identifying and treating infected individuals early, there is a reduced risk of spreading the disease to others through vectors or direct contact. Some NTDs, such as lymphatic filariasis and leprosy, can cause disabling conditions if not treated early. Early detection and intervention can prevent or reduce disability and improve the quality of life for affected individuals. Early detection can be cost-effective in the long run. It reduces the need for more extensive and expensive treatments that may be required if NTDs are diagnosed at a later stage. Timely diagnosis contributes to the success of NTDs control and elimination programs. Early detection allows for more targeted and efficient interventions, which can accelerate progress toward achieving disease control goals. Some NTDs are associated with social stigma and discrimination. Early diagnosis and treatment can help individuals avoid the social consequences of living with untreated NTDs. Advances in point-of-care diagnostic technologies make it possible to diagnose NTDs quickly and accurately in resource-limited settings, enabling immediate treatment and reducing the need for follow-up visits.

Key Market Players

• F. Hoffmann-La Roche Ltd
• Abbott Laboratories Ltd.
• Thermo Fisher Scientific Inc.
• ZeptoMetrix LLC
• InBios International, Inc.
• DiaSys Diagnostics Systems GmbH
• Genome Diagnostics Pvt. Ltd.
• Omega Diagnostics Group Plc
• Oscar Medicare Pvt Ltd.
• Coris BioConcept

Report Scope:

In this report, the Global Neglected Tropical Diseases Diagnosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neglected Tropical Diseases Diagnosis Market, By Disease:

• Dengue
• Chikungunya
• Rabies
• Buruli Ulcer
• Yaws
• Lymphatic Filariasis
• Taeniasis/Cysticercosis
• Dracunculiasis
• Others

Neglected Tropical Diseases Diagnosis Market, By Diagnostic Method:

• Conventional
• Molecular/Modern

Neglected Tropical Diseases Diagnosis Market, By Service Type:

• Centralized Service
• POC Service

Neglected Tropical Diseases Diagnosis Market, By End-Use:

• Clinical Labs
• Hospital/Clinics
• Home Healthcare

Neglected Tropical Diseases Diagnosis Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neglected Tropical Diseases Diagnosis Market.

Available Customizations:

Global Neglected Tropical Diseases Diagnosis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Neglected Tropical Diseases Diagnosis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease (Dengue, Chikungunya, Rabies, Buruli Ulcer, Yaws, Lymphatic Filariasis, Taeniasis/Cysticercosis, Dracunculiasis, others)
  • 5.2.2. By Diagnostic Method (Conventional, Molecular/Modern)
  • 5.2.3. By Service Type (Centralized Service, POC Service)
  • 5.2.4. By End Use (Clinical Labs, Hospital/Clinics, Home Healthcare)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Neglected Tropical Diseases Diagnosis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease
  • 6.2.2. By Diagnostic Method
  • 6.2.3. By Service Type
  • 6.2.4. By End Use
  • 6.2.5. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Neglected Tropical Diseases Diagnosis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease
      • 6.3.1.2.2. By Diagnostic Method
      • 6.3.1.2.3. By Service Type
      • 6.3.1.2.4. By End Use
  • 6.3.2. India Neglected Tropical Diseases Diagnosis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease
      • 6.3.2.2.2. By Diagnostic Method
      • 6.3.2.2.3. By Service Type
      • 6.3.2.2.4. By End Use
  • 6.3.3. Australia Neglected Tropical Diseases Diagnosis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease
      • 6.3.3.2.2. By Diagnostic Method
      • 6.3.3.2.3. By Service Type
      • 6.3.3.2.4. By End Use
  • 6.3.4. Japan Neglected Tropical Diseases Diagnosis Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Disease
      • 6.3.4.2.2. By Diagnostic Method
      • 6.3.4.2.3. By Service Type
      • 6.3.4.2.4. By End Use
  • 6.3.5. South Korea Neglected Tropical Diseases Diagnosis Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Disease
      • 6.3.5.2.2. By Diagnostic Method
      • 6.3.5.2.3. By Service Type
      • 6.3.5.2.4. By End Use

7. Europe Neglected Tropical Diseases Diagnosis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease
  • 7.2.2. By Diagnostic Method
  • 7.2.3. By Service Type
  • 7.2.4. By End Use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Neglected Tropical Diseases Diagnosis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease
      • 7.3.1.2.2. By Diagnostic Method
      • 7.3.1.2.3. By Service Type
      • 7.3.1.2.4. By End Use
  • 7.3.2. Germany Neglected Tropical Diseases Diagnosis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease
      • 7.3.2.2.2. By Diagnostic Method
      • 7.3.2.2.3. By Service Type
      • 7.3.2.2.4. By End Use
  • 7.3.3. Spain Neglected Tropical Diseases Diagnosis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease
      • 7.3.3.2.2. By Diagnostic Method
      • 7.3.3.2.3. By Service Type
      • 7.3.3.2.4. By End Use
  • 7.3.4. Italy Neglected Tropical Diseases Diagnosis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease
      • 7.3.4.2.2. By Diagnostic Method
      • 7.3.4.2.3. By Service Type
      • 7.3.4.2.4. By End Use
  • 7.3.5. United Kingdom Neglected Tropical Diseases Diagnosis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease
      • 7.3.5.2.2. By Diagnostic Method
      • 7.3.5.2.3. By Service Type
      • 7.3.5.2.4. By End Use

8. North America Neglected Tropical Diseases Diagnosis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease
  • 8.2.2. By Diagnostic Method
  • 8.2.3. By Service Type
  • 8.2.4. By End Use
  • 8.2.5. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Neglected Tropical Diseases Diagnosis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease
      • 8.3.1.2.2. By Diagnostic Method
      • 8.3.1.2.3. By Service Type
      • 8.3.1.2.4. By End Use
  • 8.3.2. Mexico Neglected Tropical Diseases Diagnosis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease
      • 8.3.2.2.2. By Diagnostic Method
      • 8.3.2.2.3. By Service Type
      • 8.3.2.2.4. By End Use
  • 8.3.3. Canada Neglected Tropical Diseases Diagnosis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease
      • 8.3.3.2.2. By Diagnostic Method
      • 8.3.3.2.3. By Service Type
      • 8.3.3.2.4. By End Use

9. South America Neglected Tropical Diseases Diagnosis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease
  • 9.2.2. By Diagnostic Method
  • 9.2.3. By Service Type
  • 9.2.4. By End Use
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Neglected Tropical Diseases Diagnosis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease
      • 9.3.1.2.2. By Diagnostic Method
      • 9.3.1.2.3. By Service Type
      • 9.3.1.2.4. By End Use
  • 9.3.2. Argentina Neglected Tropical Diseases Diagnosis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease
      • 9.3.2.2.2. By Diagnostic Method
      • 9.3.2.2.3. By Service Type
      • 9.3.2.2.4. By End Use
  • 9.3.3. Colombia Neglected Tropical Diseases Diagnosis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease
      • 9.3.3.2.2. By Diagnostic Method
      • 9.3.3.2.3. By Service Type
      • 9.3.3.2.4. By End Use

10. Middle East and Africa Neglected Tropical Diseases Diagnosis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease
  • 10.2.2. By Diagnostic Method
  • 10.2.3. By Service Type
  • 10.2.4. By End Use
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Neglected Tropical Diseases Diagnosis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease
      • 10.3.1.2.2. By Diagnostic Method
      • 10.3.1.2.3. By Service Type
      • 10.3.1.2.4. By End Use
  • 10.3.2. Saudi Arabia Neglected Tropical Diseases Diagnosis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease
      • 10.3.2.2.2. By Diagnostic Method
      • 10.3.2.2.3. By Service Type
      • 10.3.2.2.4. By End Use
  • 10.3.3. UAE Neglected Tropical Diseases Diagnosis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease
      • 10.3.3.2.2. By Diagnostic Method
      • 10.3.3.2.3. By Service Type
      • 10.3.3.2.4. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Neglected Tropical Diseases Diagnosis Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. F. Hoffmann-La Roche Ltd
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Abbott Laboratories Inc.
  • 16.2.1. Business Overview
  • 16.2.2. Company Snapshot
  • 16.2.3. Products & Services
  • 16.2.4. Financials (In case of listed companies)
  • 16.2.5. Recent Developments
  • 16.2.6. SWOT Analysis
• 16.3. Thermo Fisher Scientific Inc.
  • 16.3.1. Business Overview
  • 16.3.2. Company Snapshot
  • 16.3.3. Products & Services
  • 16.3.4. Financials (In case of listed companies)
  • 16.3.5. Recent Developments
  • 16.3.6. SWOT Analysis
• 16.4. ZeptoMetrix LLC
  • 16.4.1. Business Overview
  • 16.4.2. Company Snapshot
  • 16.4.3. Products & Services
  • 16.4.4. Financials (In case of listed companies)
  • 16.4.5. Recent Developments
  • 16.4.6. SWOT Analysis
• 16.5. InBios International, Inc.
  • 16.5.1. Business Overview
  • 16.5.2. Company Snapshot
  • 16.5.3. Products & Services
  • 16.5.4. Financials (In case of listed companies)
  • 16.5.5. Recent Developments
  • 16.5.6. SWOT Analysis
• 16.6. Genome Diagnostics Pvt. Ltd.
  • 16.6.1. Business Overview
  • 16.6.2. Company Snapshot
  • 16.6.3. Products & Services
  • 16.6.4. Financials (In case of listed companies)
  • 16.6.5. Recent Developments
  • 16.6.6. SWOT Analysis
• 16.7. Omega Diagnostics Group Plc
  • 16.7.1. Business Overview
  • 16.7.2. Company Snapshot
  • 16.7.3. Products & Services
  • 16.7.4. Financials (In case of listed companies)
  • 16.7.5. Recent Developments
  • 16.7.6. SWOT Analysis
• 16.8. Coris Bioconcept
  • 16.8.1. Business Overview
  • 16.8.2. Company Snapshot
  • 16.8.3. Products & Services
  • 16.8.4. Financials (In case of listed companies)
  • 16.8.5. Recent Developments
  • 16.8.6. SWOT Analysis
• 16.9. Oscar medicare Pvt Ltd.
  • 16.9.1. Business Overview
  • 16.9.2. Company Snapshot
  • 16.9.3. Products & Services
  • 16.9.4. Financials (In case of listed companies)
  • 16.9.5. Recent Developments
  • 16.9.6. SWOT Analysis
• 16.10. DiaSys Diagnostics Systems GmbH
  • 16.10.1. Business Overview
  • 16.10.2. Company Snapshot
  • 16.10.3. Products & Services
  • 16.10.4. Financials (In case of listed companies)
  • 16.10.5. Recent Developments
  • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer

관련자료